721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
G. Konecny, Andrea E. Wahner Hendrickson, Boris Winterhoff, Andrew A. Adjei, Andrew L. Kung, L-L. Miller, Michael F. Press, I. Qazi, Nathalie Scholler, Hatem Dokainish, Stephen P. Letrent, Dennis J. Slamon
Topics & Concepts
MedicineClaudinAntibody-drug conjugateCancer researchDrugConjugatePhases of clinical researchOncologyAntibodyPharmacologyMonoclonal antibodyInternal medicineChemotherapyImmunologyTight junctionGeneticsMathematicsBiologyMathematical analysisBarrier Structure and Function StudiesNeurological Disease Mechanisms and TreatmentsCell Adhesion Molecules Research